Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage.
Alzheimer’s disease
Amyloid
Non-AD dementias
White matter
amy-PET
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
12 02 2022
12 02 2022
Historique:
received:
29
03
2021
accepted:
04
11
2021
entrez:
13
2
2022
pubmed:
14
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Positron emission tomography (PET) with amyloid tracers (amy-PET) allows the quantification of pathological amyloid deposition in the brain tissues, including the white matter (WM). Here, we evaluate amy-PET uptake in WM lesions (WML) and in the normal-appearing WM (NAWM) of patients with Alzheimer's disease (AD) and non-AD type of dementia. Thirty-three cognitively impaired subjects underwent brain magnetic resonance imaging (MRI), Aβ A+ compared to A- showed a higher WML load (p = 0.049) alongside higher SUVR in all brain tissues (p < 0.01). No correlations between CSF Aβ levels and WML and NAWM SUVR were found in A+, while, in A-, CSF Aβ levels were directly correlated to NAWM SUVR (p = 0.04). CSF Aβ concentration was the only predictor of NAWM SUVR (adj R Our data provide evidence on the role of amy-PET in the assessment of microstructural WM injury in non-AD dementia, whereas amy-PET seems less suitable to assess WM damage in AD patients due to a plausible amyloid accrual therein.
Identifiants
pubmed: 35151361
doi: 10.1186/s13195-021-00933-1
pii: 10.1186/s13195-021-00933-1
pmc: PMC8841045
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Informations de copyright
© 2022. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):280-287
pubmed: 30343433
Ann Neurol. 2011 Apr;69(4):673-80
pubmed: 21337603
Ann Neurol. 2012 Oct;72(4):578-86
pubmed: 23109153
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84
pubmed: 7566337
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):126-35
pubmed: 20935330
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9304-9
pubmed: 16754874
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
J Cereb Blood Flow Metab. 2017 Jan;37(1):356-365
pubmed: 26792028
Ann Neurol. 2013 Dec;74(6):826-36
pubmed: 23536396
Curr Opin Psychiatry. 2013 May;26(3):244-51
pubmed: 23493128
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808
Int Psychogeriatr. 2003;15 Suppl 1:59-65
pubmed: 16191218
Acta Neuropathol. 1997 Apr;93(4):334-40
pubmed: 9113198
Cerebrovasc Dis. 2002;13 Suppl 2:11-5
pubmed: 11901237
Brain. 2019 Aug 1;142(8):2483-2491
pubmed: 31199475
Biochem Pharmacol. 2014 Apr 15;88(4):640-51
pubmed: 24398425
Nat Rev Neurol. 2015 Mar;11(3):157-65
pubmed: 25686760
Brain Plast. 2016 Dec 21;2(1):93-98
pubmed: 29765850
Front Neurol. 2016 Mar 31;7:53
pubmed: 27065425
J Nucl Med. 2018 Oct;59(10):1583-1589
pubmed: 29674420
Ann Neurol. 2013 Apr;73(4):529-36
pubmed: 23424091
J Alzheimers Dis. 2020;78(1):13-22
pubmed: 32925075
PLoS One. 2014 Jun 24;9(6):e100784
pubmed: 24959687
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):352-357
pubmed: 29054920
Curr Gerontol Geriatr Res. 2011;2011:826862
pubmed: 22203842
Kobe J Med Sci. 2017 Mar 13;62(5):E136-E141
pubmed: 28289271
Acta Neuropathol Commun. 2014 Aug 17;2:83
pubmed: 25129614
J Nucl Med. 2009 Feb;50(2):198-204
pubmed: 19164220